Survival Benefit Plus Safety Profile Cements T-DM1 As Successor To Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Full results from the EMILIA study show that Roche’s antibody drug conjugate T-DM1 offers a 5.8 month survival benefit in mostly second-line advanced breast cancer. Reporting results in the New England Journal of Medicine, researchers highlight the effects regardless of line of therapy and the value of antibody drug conjugates in improving safety.